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Abstract
Background
Changes in criteria and differences in populations studied and methodology have produced
a wide range of prevalence estimates for mild cognitive impairment (MCI).
Methods
Uniform criteria were applied to harmonized data from 11 studies from USA, Europe, Asia
and Australia, and MCI prevalence estimates determined using three separate definitions of
cognitive impairment.
Results
The published range of MCI prevalence estimates was 5.0%–36.7%. This was reduced with
all cognitive impairment definitions: performance in the bottom 6.681% (3.2%–10.8%); Clini-
cal Dementia Rating of 0.5 (1.8%–14.9%); Mini-Mental State Examination score of 24–27
(2.1%–20.7%). Prevalences using the first definition were 5.9% overall, and increased with
age (P < .001) but were unaffected by sex or the main races/ethnicities investigated (Whites
and Chinese). Not completing high school increased the likelihood of MCI (P .01).
Conclusion
Applying uniform criteria to harmonized data greatly reduced the variation in MCI preva-
lence internationally.
Introduction
Mild cognitive impairment (MCI) refers to cognitive decline from a previous level of function-
ing, both subjectively and by objective evidence. The condition was first conceptualized in the
1980s, at which time it focused on memory impairment and was thought to be a transitional
stage between normal cognitive ageing and Alzheimer’s disease (AD) [1], and assigned to cor-
responding stages on both the Clinical Dementia Rating (CDR; rating of 0.5) [2] and Global
Deterioration Scale (stages 2 and 3) [3]. While individuals with MCI due to AD may go on to
develop dementia due to AD, others with MCI may develop different subtypes of dementia [4–
7]. It has also become apparent that MCI is not necessarily a pre-dementia syndrome, as many
individuals with MCI do not show progression of their cognitive deficits, and may in some
cases revert to normal cognition [6, 8, 9]. Accordingly, the concept of MCI has evolved to
accommodate heterogeneity in outcomes and aetiologies, in part through the development of
MCI subtypes with greater potential clinical and prognostic value [1, 10]. The major MCI sub-
types are amnestic (aMCI), involving episodic memory impairment (with or without
impairment in other cognitive domains), and non-amnestic (naMCI), involving impairment in
cognitive domains other than memory. Of these subtypes, aMCI is considered more likely to
progress to AD, and naMCI more likely to progress to other types of dementia [10].
The level of cognitive decline associated with MCI is greater than expected for age, but not as
severe as that associated with dementia. Another point of difference is retention of independence
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in activities of daily living (ADLs) with MCI [11, 12]. This can be difficult to establish however,
as people with MCI can show impairments in high level or complex functional tasks [11, 13]. A
decrease in the ability to perform such tasks can predict a decline fromMCI to dementia [8].
Since MCI imposes a health burden of its own and increases the risk of dementia, it is
important to reliably estimate the prevalence of MCI around the globe. However, a recent
review found that the reported prevalence of MCI varies widely across international studies,
from around 3% to 42% [14]. This high level of variability in reported MCI prevalence poses
problems for public health policy and planning. Some of the variation may be associated with
regional and/or ethnic differences. For example, the prevalence of aMCI in India is reportedly
more than five times higher than in China, despite standardization for age, sex and education
[15]. Another study found a higher prevalence of naMCI in Blacks than in Whites from a simi-
lar geographical location, even when sex and education were controlled [16]. That study also
found the prevalence of aMCI to increase with age among men and blacks. Others have found
that the prevalence of MCI increased with age [17, 18], or that men had a higher prevalence of
either MCI [18] or aMCI [19]. Education also appears to influence the prevalence of MCI [17].
While findings like these suggest that differences in location and demographic make-up may
contribute to the wide variation in reported prevalence of MCI, a significant proportion can be
attributed to differences in definition and methodology [14]. For example, studies have not
been consistent in how they have defined objective cognitive impairment. Small changes to ele-
ments of this criterion, such as the threshold for impairment and the number of sub-threshold
cognitive test results required, can greatly affect the prevalence of MCI found [20]. A further
issue is the use of only global scales by many studies, with limited forms of neuropsychological
testing less likely than comprehensive test batteries to reliably identify MCI [21].
We have recently developed an international consortium—Cohort Studies of Memory in an
International Consortium (COSMIC) [22]–which has brought together data from cohort stud-
ies of cognitive aging internationally. The goal of this study was to harmonize these data and
apply uniform diagnostic criteria to more reliably estimate MCI prevalence across different
geographical and ethnocultural regions. We present data from three studies in USA, four in
Europe, two in Asia, and two in Australia.
Materials and Methods
Contributing studies and participants
Cross-sectional analyses of 11 longitudinal population-based studies of cognitive aging (listed
in Table 1, with abbreviations) were performed. Rather than the full population of each study,
we used samples comprising individuals aged 60 or more years who were not identified as hav-
ing dementia and/or did not have a CDR [34] 1. Any individuals with missing age, sex or
dementia status data were excluded. A number of samples did not require exclusions for
dementia because individuals with dementia were already omitted during the recruitment
phase of the study. Table 2 shows the demographic characteristics of the samples used in our
analyses, including the main race or ethnicity represented (White in 7 studies and Chinese in 2
studies). As a project of the COSMIC collaboration, the present study was performed with
approval from the University of New South Wales Human Research Ethics Committee (Ref: #
HC12446). Each of the 11 extant studies contributing data to the present study had previously
obtained ethics approval from their respective institutional review boards, and all participants
within the studies provided consent (for details see the references listed in Table 1). The partic-
ular use of these data for the present study did not warrant further participant consent, with
de-identified health data not considered to be protected health information under current
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Table 2. Sample characteristics.
Characteristic CFAS EAS ESPRIT HK-MAPS Invece.Ab MoVIES PATH SLAS Sydney
MAS
WHICAP ZARADEMP
(N = 2050) (N = 1954) (N = 2189) (N = 786) (N = 1267) (N = 1276) (N = 1973) (N = 3950) (N = 1037) (N = 3991) (N = 4415)
Age (yrs)
Mean ± SD 75.8 ± 7.3 78.3 ± 5.4 73.1 ± 5.6 72.3 ± 7.2 71.2 ± 1.3 74.2 ± 5.4 70.6 ± 1.5 68.5 ± 6.3 78.8 ± 4.8 76.4 ± 6.5 73.4 ± 9.3
Range 64–105 63–100 65–96 60–96 70–75 66–97 68–74 60–97 70–90 63–103 60–102
Sex
Female 1289
(62.9)
1191
(61.0)
1277
(58.3)
422 (53.7) 684 (54.0) 775 (60.7) 953 (48.3) 2382
(60.3)
572 (55.2) 2684 (67.3) 2518 (57.0)
Male 761 (37.1) 763 (39.0) 912 (41.7) 364 (46.3) 583 (46.0) 501 (39.3) 1020
(51.7)
1568
(39.7)
465 (44.8) 1307 (32.7) 1897 (43.0)
Education
Less than
completed high
school
195 (9.5) 428 (21.9) 550 (25.1) 686 (87.3) 1150
(90.8)
500 (39.2) 466 (23.6) 3449
(87.3)
437 (42.1) 2163 (54.2) 3838 (86.9)
Completed
high school
1399
(68.2)
906 (46.4) 911 (41.6) 49 (6.2) 90 (7.1) 544 (42.6) 202 (10.2) 73 (1.8) 177 (17.1) 733 (18.4) 128 (2.9)
Technical/
college diploma
286 (14.0) 97 (5.0) 210 (9.6) 8 (1.0) NAa 193 (15.1) 610 (30.9) 265 (6.7) 112 (10.8) 480 (12.0) 281 (6.4)
University
degree
148 (7.2) 478 (24.5) 516 (23.6) 42 (5.3) 27 (2.1) 39 (3.1) 674 (34.2) 161 (4.1) 311 (30.0) 605 (15.2) 131 (3.0)
Missing data 22 (1.1) 45 (2.3) 2 (0.1) 1 (0.1) 0 (0.0) 0 (0.0) 21 (1.1) 2 (0.1) 0 (0.0) 10 (0.3) 37 (0.8)
Race/ethnicity White White
(67%);
Black
(27%)
White Chinese White White White Chinese White Hispanic
(48%);
Black
(30%);
White
(21%)
White
NA = not applicable. Data are n (%) unless stated otherwise. N is for the contributed sample that includes individuals from the full study sample without
dementia and with no missing data on the baseline dementia, age and sex variables. Age corresponds to the assessment wave for which data were
provided: baseline for all studies except MoVIES (wave 2) and PATH (wave 3). For race/ethnicity, the sample was comprised entirely or predominantly of
that shown unless otherwise indicated.
a Technical/college diploma could not be distinguished from Completed high school for Invece.Ab.
doi:10.1371/journal.pone.0142388.t002
Table 1. Contributing studies.
Study Abbreviation Country Reference
Cognitive Function & Ageing Studies CFAS UK Brayne et al. [23]
Einstein Aging Study EAS USA Katz et al. [16]
Etude Santé Psychologique Prévalence Risques et Traitement ESPRIT France Ritchie et al. [24]
Hong Kong Memory and Ageing Prospective Study HK-MAPS Hong Kong Wong et al. [25]
Invecchiamento Cerebrale in Abbiategraso Invece.Ab Italy Guaita et al. [26]
Monongahela Valley Independent Elders Survey MoVIES USA Ganguli et al. [27]
Personality and Total Health Through Life Project PATH Australia Anstey et al. [28]
Singapore Longitudinal Ageing Studies SLAS Singapore Feng et al. [29, 30]
Sydney Memory and Ageing Study Sydney MAS Australia Sachdev et al. [31]
Washington Heights Inwood and Columbia Aging Project WHICAP USA Tang et al. [32]
Zaragoza Dementia Depression Project ZARADEMP Spain Lobo et al. [33]
doi:10.1371/journal.pone.0142388.t001
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research principles (e.g., as per the Privacy Rule proposed by the National Institute of Health,
USA http://privacyruleandresearch.nih.gov/research_repositories.asp).
Measures and harmonization
Of the 11 contributing studies, nine provided raw data needed to make classifications of MCI
(summarized in S1–S5 Tables). The Sydney team processed these data, which were harmo-
nized, when necessary, and pooled. The other two studies, CFAS and Invece.Ab, conducted
analyses in-house using the protocols developed for this report. Baseline or wave 1 data were
used for all studies except two that did not have all variables needed to make MCI classifica-
tions until later waves: MoVIES [27] provided data for wave 2 (2 years after baseline), and
PATH [28] for wave 3 (8 years after baseline). Data for SLAS are for two cohorts, SLAS-1
recruited 2003–2004 and SLAS-2 recruited 2008–2011, and for whom the same core measure-
ments and procedures were used [29, 30].
Demographics
Information included age, sex and education. Education data were harmonized by forming a
variable with four categories: Less than high school completion; high school completion; tech-
nical or college diploma; university degree (as shown in S6 Table). Note that we use the term
college diploma in an international context, referring to courses of less duration and standard
than a bachelor’s degree that are typically provided by technical, applied, or more vocationally
oriented institutions rather than universities. Each of the contributing studies helped determine
how the data representing their local education system was best transformed to the four catego-
ries we used.
Functional ability
A variety of instruments assessing ADLs and instrumental ADLs (IADLs) was used across the
studies (S7 Table), with the Lawton & Brody IADL Scale [35] used by five studies. Six common
and compatible IADL items were chosen for harmonization: telephone, food preparation, med-
ications, shopping, finances, and transport. For each of these items, the Lawton & Brody IADL
Scale assigns a score of 0 to dependent responses and 1 to independent responses. We pro-
duced a dichotomized variable of 0 (dependence) and 1 (independence) for each item by
matching responses from different instruments to this scoring system. The strictness or level of
assistance required for a classification of dependence varies between items on the Lawton &
Brody Scale, and thus a response from another instrument such as “Yes, some difficulty” could
be considered independent on one of the harmonized items but dependent on another. For full
details of this procedure see S8 and S9 Tables.
Cognitive ability or status
All studies, except for ZARADEMP, administered a neuropsychological test battery; addition-
ally, all except for EAS andWHICAP used the Mini-Mental State Examination (MMSE). How-
ever, EAS administered the Blessed Information-Memory-Concentration test, and a validated
formula was used to convert scores for this test to MMSE scores [36]. More than half of the
studies administered the CDR Scale (Table 3). There was limited overlap in the neuropsycho-
logical tests used between studies, and each test score was allocated to one of five cognitive
domains: memory, attention/processing speed, language, executive function, and perceptual-
motor. However, the perceptual-motor domain was not used in classifying MCI as scores could
not be formed for four studies (ESPRIT, HK-MAPS, Invece.Ab, and PATH). Tests were
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allocated to domains to be consistent with common practice (as outlined in the S1 Text and
S10–S14Tables) [37–39]. Domain scores were calculated separately for each study, using infor-
mation from within the study only. The first step was to adjust test scores for age, sex and edu-
cation, and for all interactions between these variables using regression analyses. Such
adjustments are standard practice in neuropsychological assessment because these variables
may significantly affect test performance [37]. Further, the use of age and education adjusted
norms has been particularly recommended when assessing the objective cognitive impairment
criterion for MCI [11]. Our use of these adjustments should therefore have yielded prevalences
for MCI similar to those found were each study to independently make new classifications of
MCI using the same set of recent international guidelines. The adjusted test scores were then
transformed to Z-scores using the mean and SD of the study sample as normative values. It has
been argued and shown that more equivalent and accurate comparisons of cognitive perfor-
mance between countries are facilitated by the use of country-specific norms [40]. However,
for many countries, including those represented by the studies contributing to this investiga-
tion, there are no published normative data available. Indeed, a survey of the COSMIC member
studies shows that even when norms for particular cognitive tests are available they are often
not age-appropriate for elderly samples. Thus, the largely incomplete availability of external
norms helped determine our choice to use study-specific internal norms. After forming Z-
scores for the tests on the basis of these internal norms, composite scores for each domain were
calculated as the mean of the Z-scores of the relevant component tests. These composite scores
were themselves then transformed to Z-scores to ensure that all domains had means of 0 and
SDs of 1 within each study. Full details and reasons for how domain scores were calculated are
in S1 Text.
Table 3. Prevalence of mild cognitive impairment: subtypes, and as based on Clinical Dementia Ratings and Mini-Mental State Examination
scores.
aMCI naMCI MMSE CDR
Study Crude Standardized Crude Standardized Crude Standardized Crude Standardized
CFAS NA NA NA NA 11.3 (9.1–13.9) 13.9 (11.7–16.1) NA NA
EAS 1.8 (1.3–2.6) 1.4 (0.9–1.9) 2.6 (1.9–3.4) 2.0 (1.4–2.6) 10.3 (8.9–11.9) 6.7 (5.7–7.7) 6.6 (5.4–8.0) 5.2 (4.1–6.2)
ESPRIT 1.2 (0.8–1.7) 1.3 (0.7–1.8) 3.5 (2.8–4.4) 3.7 (2.8–4.5) 9.2 (8.1–10.6) 9.4 (8.0–10.7) NA NA
HK-MAPS 1.0 (0.4–2.6) 0.5 (0.0–0.9) 4.4 (2.9–6.9) 5.2 (2.7–7.6) 14.4 (11.8–17.3) 14.5 (11.7–17.3) 13.6 (11.3–16.2) 14.9 (12.1–17.8)
Invece.Ab 3.9 (3.0–5.2) 3.0 (2.3–3.7) 4.4 (3.3–5.8) 4.0 (3.1–4.9) 10.7 (9.0–12.7) 9.9 (8.5–11.2) NA NA
MoVIES 2.6 (1.9–3.6) 2.6 (1.7–3.5) 4.7 (3.6–6.0) 5.1 (3.8–6.4) 18.5 (16.4–20.8) 19.1 (16.8–21.4) 1.5 (1.0–2.3) 1.8 (1.0–2.6)
PATH 1.0 (0.6–1.6) 1.0 (0.6–1.5) 2.3 (1.6–3.1) 2.4 (1.7–3.0) 1.3 (0.9–2.0) 2.1 (1.5–2.7) NA NA
SLAS 2.0 (1.4–2.9) 2.2 (1.3–3.1) 3.2 (2.4–4.2) 2.8 (1.7–3.9) 6.5 (5.5–7.6) 6.7 (5.5–8.0) 13.6 (11.3–16.3) 13.9 (10.5–17.3)
Sydney MAS 4.0 (2.9–5.5) 3.6 (2.5–4.7) 6.7 (5.3–8.6) 6.2 (4.7–7.6) 16.7 (14.4–19.3) 17.4 (15.1–19.6) 9.2 (7.4–11.3) 9.6 (7.8–11.3)
WHICAP 1.6 (1.3–2.1) 1.5 (1.1–1.9) 4.8 (4.0–5.6) 4.6 (3.8–5.4) NA NA 9.5 (8.6–10.5) 9.3 (8.3–10.2)
ZARADEMP NA NA NA NA 19.7 (18.4–21.1) 20.7 (19.2–22.1) NA NA
Total 2.0 (1.7–2.2) 2.0 (1.7–2.2) 3.9 (3.6–4.2) 3.9 (3.6–4.2) 12.0 (11.5–12.5) 12.0 (11.5–12.4) 8.5 (8.0–9.2) 9.0 (8.4–9.6)
aMCI = amnestic mild cognitive impairment; naMCI = non-amnestic mild cognitive impairment; CDR = Clinical Dementia Rating; MMSE = Mini-Mental
State Examination; NA = not applicable. Values are percentage prevalence (95% conﬁdence interval). The objective cognitive impairment criteria for these
classiﬁcations was for aMCI: performance in the bottom 6.681% of the relevant study for the memory domain; naMCI: performance in the bottom 6.681%
of the relevant study for at least one harmonized cognitive domain other than and excluding memory; CDR: a rating of 0.5; MMSE: a score of 24–27.
Standardized prevalence estimates were directly standardized for age group and sex, with the standard population being the total sample of all studies
included in the analysis; data were imputed for the missing age ranges within Invece.Ab, PATH and Sydney MAS.
doi:10.1371/journal.pone.0142388.t003
Mild Cognitive Impairment Internationally
PLOS ONE | DOI:10.1371/journal.pone.0142388 November 5, 2015 6 / 19
Subjective cognitive complaint or concern
The means by which the contributing studies ascertained the presence or absence of a cognitive
complaint or concern varied widely. Some studies asked a single question of the participant,
while others used different and sometimes multiple approaches that included clinical impres-
sion, standardized instruments, and informant reports. We attempted to minimize any biases
associated with these differences, particularly those related to having different numbers of
opportunities to endorse a complaint, by choosing to use only the most generalized question
asked of the participant (either in isolation or extracted from a longer instrument) from each
study (see S15 Table). This was also the default option given that some studies only had one rel-
evant item. All of the questions addressed memory only, except those used by SLAS, which also
addressed thinking or other mental abilities. We dichotomized the responses to indicate either
the presence or absence of a subjective cognitive complaint or concern.
Classification of MCI
MCI was classified using the four generally accepted criteria: absence of dementia, no or mini-
mal functional impairment, subjective memory/cognitive complaint or concern, and objective
cognitive impairment [12]. Most studies reported making classifications of dementia using
DSM-IV criteria (see S16 Table). Note that a number of studies excluded any individuals with
dementia at the recruitment stage of their study. Functional impairment was defined as depen-
dence in two or more harmonized IADL items (the handling of missing data is detailed in S1
Text). Cognitive complaints or concerns were determined as above. Objective cognitive
impairment for each cognitive domain was a score within the bottom 6.681% of the scores for
that domain within the relevant study’s sample, which is the equivalent of impairment being
defined as scores more than 1.5 SDs below the mean. A classification of MCI required
impairment in any of the four domains used. Impairment on the memory domain was needed
for aMCI, and impairment on any of the other domains (without memory impairment) for
naMCI; individuals with data for fewer than three of the non-memory domains were included
if impairment was present in one or more domain, otherwise excluded. For other analyses,
objective cognitive impairment was defined as an MMSE score from 24 to 27 (inclusive), or as
a CDR of 0.5. An MMSE score of 24–27 has been previously used to define a range of milder
forms of cognitive impairment, including MCI [41, 42], mild cognitive decline [43] and mild
AD [44], and a CDR of 0.5 is a commonly-used criteria for MCI (e.g., [45, 46]).
Statistical analysis
The Sydney team performed all analyses of the harmonized and pooled data. Five different MCI
classifications were made: MCI and its aMCI, and naMCI subtypes using harmonized cognitive
domain scores for determining objective cognitive impairment; and MCI using each of MMSE
and CDR scores for this criterion. For each type of classification, only individuals with complete
data for all four MCI criteria were included. Crude prevalence was determined for men and
women in three age groups (60–69, 70–79 and 80–89 yrs). TheWilson score method described,
evaluated and endorsed by Newcombe [47] was used to determine 95% confidence intervals
(CIs), and chi-square tests were used to make comparisons. Prevalence estimates and CIs directly
standardized for age and sex were calculated (for details see S1 Text). For studies with partici-
pants in only one or two of the age groups, data for the remaining age group or groups were gen-
erated using a multiple imputation procedure (outlined in S1 Text). Associations between
educational level and MCI were investigated with logistic regressions that controlled for age and
sex. The two studies that provided results rather than raw data (CFAS and Invece.Ab) used the
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standard protocols developed for this report. The analyses were done using IBM SPSS Statistics
20, and the imputations done using the R-package mice 2.21.
Results
Sample description
The demographic characteristics of the cohorts are provided in Table 2. The samples varied in
size from 786 (HK-MAPS) to 4,415 (ZARADEMP), with a median of 2,000, and total sample
of 24,888 (59.3% women; mean age 73.6 yrs). The purpose and design of both Invece.Ab [26]
and PATH [28] led to them having narrower age cohorts than the other contributing studies.
The sample sizes for each approach for classifying MCI are shown in S17 Table.
Prevalence of MCI
Fig 1 shows the prevalences of MCI previously published by the contributing studies, alongside
the crude and standardized prevalences obtained using COSMIC protocols that defined cogni-
tive impairment as performance in the bottom 6.681%. With this criterion, the crude preva-
lence was 5.9 (5.5–6.3)% overall, and increased with age: from 4.5% among 60–69 year-olds to
5.8% among 70–79 year-olds (χ2 = 6.80, df = 1, P = .009), and to 7.1% among 80–89 year-olds
(χ2 = 5.28, df = 1, P = .022 vs. 70–79 year-olds). The crude prevalence for men was higher
among 70–79 year-olds than among 60–69 year-olds (χ2 = 4.62, df = 1, P = .032), but not signif-
icantly higher among 80–89 year-olds than 70–79 year-olds (see Fig 2). For women, the only
increase was from 60–69 year-olds to 80–89 year-olds (χ2 = 7.82, df = 1, P = .005). There were
no significant differences between men and women within any of the age groups. The average
age- and sex-standardized prevalence for 60–89 year-olds was 5.8 (5.4–6.2)%. The standardized
prevalence differed across the studies (χ2 = 94.64, df = 8, P< .001), but not between Chinese
(5.2%, 95% CI = 4.1–6.4%) andWhites (5.8%, 5.3–6.3%; χ2 = 0.76, df = 1, P = .383).
Higher figures were obtained when MMSE scores 24–27 were used as the criterion, with an
overall total crude prevalence of 12% (see Table 3). Crude prevalence estimates were greater
among 70–79 year-olds than 60–69 year-olds for men (χ2 = 5.80, df = 1, P = .016), and greater
among 80–89 year-olds than 70–79 year-olds for both men (χ2 = 43.10, df = 1, P< .001) and
women (χ2 = 46.07, df = 1, P< .001; Fig 2). There were no significant differences between men
and women within any of the age groups. Standardized prevalence estimates were significantly
higher for White populations (12.9%, 12.3–13.4%) than for Chinese (8.6%, 7.4–9.7%; χ2 =
42.34, df = 1, P< .001). All studies except WHICAP had MMSE scores, and it is noteworthy
that the Spanish study (ZARADEMP), which only had MMSE scores, yielded the highest crude
and standardized prevalence figures using this measure, thereby influencing the overall preva-
lence estimates. The CDR, administered by only six studies, yielded prevalence estimates of
8.5% (overall crude) and 9.0% (overall standardized), which were in between those based on
MMSE scores and those based on harmonized cognitive domain scores (see Table 3). CDR-
based prevalence estimates were significantly greater among 80–89 year-olds than 70–79 year-
olds for both men (χ2 = 4.74, df = 1, P = .030) and women (χ2 = 4.46, df = 1, P = .035; Fig 2).
The correspondence between the prevalence estimates with MMSE or CDR was low.
The range of MCI prevalence estimates published by the contributing studies was 5.0%–
36.7% (see Fig 1). This considerable variation in estimates was reduced with all three of the def-
initions for cognitive impairment that we used: performance in the bottom 6.681% (3.2%–
10.8%); CDR of 0.5 (1.8%–14.9%); MMSE score of 24–27 (2.1%–20.7%).
Mild Cognitive Impairment Internationally
PLOS ONE | DOI:10.1371/journal.pone.0142388 November 5, 2015 8 / 19
Prevalence of MCI subtypes
The overall crude prevalence of aMCI was 2.0% and of naMCI 3.9% (see Table 3). Prevalence
estimates of aMCI did not differ significantly across age groups or by sex (S1 Fig). Prevalence
estimates of naMCI were greater among 70–79 year-olds than 60–69 year-olds for men (χ2 =
5.06, df = 1, P = .024), and greater among 80–89 year-olds than 70–79 year-olds for women (χ2
= 4.95, df = 1, P = .026), but there were no sex differences. On the basis of standardized esti-
mates, there were no differences in the prevalence of either subtype between Whites (2.1%,
1.8–2.4% for aMCI and 3.8%, 3.4–4.2% for naMCI) and Chinese (1.8%, 1.1–2.5% for aMCI and
Fig 1. Prevalence estimates of mild cognitive impairment previously published and as obtained using COSMIC protocols. Error bars indicate the
upper limits of 95% confidence intervals. For the crude and standardized prevalence estimates obtained using COSMIC protocols, the criterion for objective
cognitive impairment was performance in the bottom 6.681% for the study on at least one harmonized cognitive domain. Estimates were directly
standardized for age and sex, with the standard population being the total sample of all studies included in the analysis; data were imputed for missing age
ranges within Invece.Ab, PATH and Sydney MAS. SLAS had not previously published prevalence estimates of mild cognitive impairment (MCI), and a
published estimate for MoVIES was for amnestic MCI only [19]. CFAS and ZARADEMP did not have neuropsychological test data from which harmonized
cognitive domain scores could be derived. Published prevalence estimates are for baseline, except for PATH (wave 3, the first assessment when all relevant
data for classifying MCI were obtained). References for the published estimates shown are: CFAS [48]; EAS [16]; ESPRIT [24]; HK-MAPS [25]; Invece.Ab
[49]; PATH [50]; Sydney MAS [51]; WHICAP [52]; ZARADEMP [53]. Note that the HK-MAPS sample was over-represented by individuals considered to be at
increased risk of conversion to dementia, and the prevalence estimates for MCI shown are likely to overestimate those for the broader population [25].
doi:10.1371/journal.pone.0142388.g001
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3.6%, 2.6–4.6% for naMCI; χ2 = 0.19, df = 1, P = .663 and χ2 = 0.39, df = 1, P = .532,
respectively).
Education and MCI
Compared to the lowest level (not having completed high school), all higher levels of education
conveyed a reduced likelihood of MCI. The odds ratios were 0.58 (P< .001) for having com-
pleted high school, 0.55 (P< .001) for technical college or a diploma, and 0.73 (P = .002) for a
university degree (S18 Table). Controlling for education however only partially reduced varia-
tion in prevalence across studies (further described in S2 Text).
Effects of age on subjective memory complaints, functional
independence, and objective cognitive impairment
We conducted supplementary analyses to determine the extent to which effects of age on the
harmonized variables used to classify MCI may have contributed to our finding that the
Fig 2. Crude prevalence estimates of mild cognitive impairment (MCI) amongmen and women of different age groups. Error bars indicate upper
limits of 95% confidence intervals. Asterisks indicate a significant difference from: * 60–69 years; ** 70–79 years. There were no significant differences
between men and women of the same age group for any classification approach. The objective cognitive impairment criteria for the classifications was
performance in the bottom 6.681% of the relevant study for at least one harmonized cognitive domain (mild cognitive impairment), a Clinical Dementia Rating
(CDR) of 0.5, or a Mini-Mental State Examination (MMSE) score 24–27.
doi:10.1371/journal.pone.0142388.g002
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prevalence of MCI increased with age (values are detailed in S1–S3 Tables). The rate of subjec-
tive memory complaints increased with age, from 26.4% among 60–69 year-olds to 30.7%
among 70–79 year-olds (χ2 = 33.95, df = 1, P< .001), and to 37.5% among 80–89 year-olds (χ2
= 67.58, df = 1, P< .001 vs. 70–79 year-olds). Conversely, the rates of functional independence
decreased with age, from 97.7% among 60–69 year-olds to 94.5% among 70–79 year-olds (χ2 =
112.63, df = 1, P< .001), and to 83.8% among 80–89 year-olds (χ2 = 480.77, df = 1, P< .001
vs. 70–79 year-olds). There was no significant difference in the rate of objective cognitive
impairment between 60–69 year-olds (20.6%) and 70–79 year-olds (19.5%; χ2 = 1.84, df = 1, P
= .175), though the rate was higher for 80–89 year-olds (24.5%) than for 70–79 year-olds (χ2 =
30.06, df = 1, P< .001).
Discussion
We analysed pooled data from 11 international cohort studies and found that applying uni-
form criteria to harmonized data greatly reduced the variation in MCI prevalence internation-
ally. This was the case with each of the three definitions of cognitive impairment that we used
to make separate classifications of MCI: performance in the bottom 6.681%, CDR of 0.5, and
MMSE score of 24–27. The overall estimates found with these methods were between 6% and
12%, at the lower end of the 3% to 42% range reported by the international studies included in
a recent review [14]. Our estimates for the studies contributing to the present investigation are
also mostly lower than they themselves have previously published (Fig 1), which is due to the
differential criteria used. Differences in the criteria for objective cognitive impairment may be
particularly relevant [20], even in some cases where the same −1.5 SD threshold recommended
by published criteria [11, 54] is used (and as per our definition of impairment being perfor-
mance in the bottom 6.681%). For example, the criterion for impairment in the Sydney MAS
was performance on any one of 12 individual neuropsychological tests being 1.5 SDs below
published normative values [51]. In contrast, the COSMIC criterion for impairment was one of
only four cognitive domain scores<−1.5 SD. The COSMIC approach of applying performance
thresholds to domain scores, rather than to individual tests, was taken to prevent different
prevalence estimates of MCI resulting merely from differences in the number of tests adminis-
tered. The use of the −1.5 SD threshold in COSMIC also made a difference; e.g., EAS had previ-
ously used a 20th percentile (approximately −0.84 SD) threshold [16]. For purposes of
harmonization, we used only the most generalized self-report item from each study to ascertain
the presence of a cognitive complaint. However, some of the contributing studies administered
multiple cognitive complaint questions and/or scales to their participants, and sometimes also
sought informant reports. With multiple opportunities, a participant may be more likely to
endorse a complaint and thus more likely to be classified as having MCI (if meeting the other
criteria). This could help account for why the prevalences of MCI we determined are lower
than those previously reported by some studies. It must also be stated that the exclusion of
dementia for this analysis altered the denominator in some of the studies, thereby influencing
the prevalence estimates, albeit to a small extent only. Note that not all studies contained par-
ticipants with dementia in their original samples, with some excluding individuals with demen-
tia at the time of recruitment.
There being higher prevalence of MCI when less stringent criteria are applied reinforces the
need for a harmonized approach. Compared to the −1.5 SD threshold for cognitive impairment
we used, the DSM-5 definition of mild neurocognitive disorder recommends a less stringent
criterion of −1.0 to −2.0 SD, without specifying how many tests should comprise a domain. Of
course, the use of a threshold assumes that normative data are available for each test. We
derived norms from the non-demented population of the same study. This approach offers the
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advantage of removing potential sociocultural and ethnic biases in any external source of nor-
mative data uniformly applied across all studies, and a similar approach was used by the 10/66
group [15]. A disadvantage is that it will mask the true extent of real differences in the popula-
tions themselves. In our study, use of this approach produced nearly identical percentages of
impairment within each cognitive domain investigated. However, there were overall differences
in impairment between studies because of differences in the number of individuals with
impairment in multiple domains (see S3 Table). Even so, differences in MCI criteria other than
objective cognitive impairment, including subjective memory complaints and functional inde-
pendence, should be considered as major influences on the differences in MCI prevalence esti-
mates we observed when using this particular approach.
Differences in MCI prevalence between studies may also stem from differences in method-
ology other than MCI criteria, including differences in recruitment procedures. It has been
shown that including institutionalized individuals and obtaining proxy-based data for others
either unable or unwilling to participate directly can elevate estimates of moderate and severe
dementia prevalence [55]. A similar effect could be expected for MCI, and thus differences in
response rates and the inclusion of institutionalized individuals in 3 of the 11 samples are likely
to have contributed to some of the pre-existing and remaining (post-harmonization) variance
in MCI prevalence across the studies we investigated.
In our study, the prevalence was about twice as high if MMSE was used to define objective
impairment. The MMSE has many limitations when used for this purpose: it has age and edu-
cation biases [56]; it shows cultural and linguistic artefacts [57]; it is strongly influenced by ver-
bal memory function while not covering all domains of cognition adequately; and, though
adopted as a definition for MCI by others [41, 42], the range of 24–27 for MCI has not been
validated. Prevalence estimates using a CDR score of 0.5 as the basis for cognitive impairment
were in between the estimates based on MMSE scores and those based on harmonized cogni-
tive domain scores. A CDR score of 0.5 is a commonly-used criteria for MCI (e.g., [45, 46]).
However, the use of CDR for the diagnosis of MCI has not been established; it is informant-
dependent and requires clinical judgment that is difficult to standardize, and its correspon-
dence with the generally accepted criteria for MCI is low in our study.
We did not find any significant sex differences in MCI prevalence. This is consistent with
some previous literature [7, 15], but a possibly higher prevalence in men has also been reported
[18]. We did find that the prevalence of MCI increased with age, though the pattern across age
groups differed between men and women. There were also differences in how the prevalence of
MCI increased with age across the three definitions of cognitive impairment we used. Preva-
lences determined on the basis of MMSE scores exhibited the largest increase with age, whereas
those determined on the basis of performance in the bottom 6.681% showed the smallest (see
Fig 2). The smaller changes observed with the latter definition are not surprising, given that age
effects were likely underestimated by the use of age-adjusted neuropsychological test scores.
Supplementary analyses on the harmonized variables used in classifying MCI suggest that an
increase across the age groups in subjective memory complaints helped drive the increase in
MCI with age. Conversely, rates of functional independence decreased with age. The increase
in prevalence with age we found for MCI based on MMSE scores comes closest (of the different
definitions used) to matching the exponential rise with age found for the global prevalence of
dementia [58]. That study also found the global prevalence of dementia to be greater among
women than among men, which differs from our findings for MCI. This suggests that MCI
should not be conceptualized solely as a pre-dementia syndrome, but as a distinct syndrome
with some overlap with pre-dementia. This, and MCI being associated with subtle impairments
in high level or complex functional tasks [11, 13] that pose a burden on the individual and soci-
ety, makes the prevalence of MCI of great interest in its own right.
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We observed higher rates of MCI for White European populations than for Chinese when
these were based on MMSE scores. Direct comparisons of dementia rates between Chinese and
Whites appear to be scarce, and even more so for MCI. Previous work suggests the possibility
of lower rates of dementia in China and Singapore compared to rates for the USA and Europe
[59]. While loosely consistent with this, our findings of higher rates of MCI among Whites
should be viewed very tentatively for a number of reasons. These include limitations in using
the MMSE to classify MCI (as described above), there being no difference in rates between Chi-
nese andWhites with the other definitions for MCI, and neither of the Chinese samples we
investigated coming from mainland China.
The prevalence of MCI was lower in those with higher education, despite the neuropsycho-
logical test results having been corrected for education. Compared to not having completed
high school, an apparent protective effect was found for all levels of education from having
completed high school and above. However, though this effect was significant for having ter-
tiary education (odds ratio = 0.73), it was not as strong as for either having completed high
school (odds ratio = 0.58) or technical college/diploma (odds ratio = 0.55). The likely protective
effect of education is consistent with the literature of a lower prevalence of dementia [60] and
cognitive decline [61] in those with higher education.
It is noteworthy that our analysis showed higher prevalence estimates of naMCI to aMCI by
a ratio of nearly 2:1, which is consistent with some studies [62, 63] but contrary to another [7].
The literature, however, has not examined naMCI with the same rigor as aMCI, and the com-
mon use of the 1999 Mayo Clinic criteria for MCI [54] conflates aMCI with MCI. It is arguable
that our finding is artefactual since there are three non-memory domains, and it is thus statisti-
cally more likely for an individual to have impairment in a non-memory domain than in the
sole memory domain. However, it may also be the case that a higher prevalence of naMCI
stems from this being a more heterogeneous and unstable condition than aMCI, as evidenced
by less progression to dementia and higher rates of reversion to normal cognition upon follow-
up [64–66]. This issue deserves further study as it has potentially important clinical
implications.
Strengths of our study include the large number of independent cohorts examined from
diverse geographical, ethnic and sociocultural groups, and rigorous standardization of data.
However, there are also some weaknesses. While the samples were epidemiologically derived,
they were from specific regions and cannot be said to be necessarily representative of the coun-
tries or entire populations they come from. While all studies are longitudinal, this analysis is
cross-sectional. Different instruments were used in the different studies, and ideally the harmo-
nization process should begin at the time of study inception and not retrospectively. Cultural
effects are also not to be ignored. For example, differences in rates of functional independence
between studies could be influenced by cultural differences in reporting disability [67]. This in
turn could contribute to differences in the estimated prevalences of MCI between studies
(though the study with the lowest rate of dependence, ESPRIT, also had a lower prevalence of
MCI than the study with the highest rate of dependence, WHICAP). Two studies had Chinese
populations, but both were in high income countries, and while the American studies had
some participants from black and Hispanic communities, these data are not presented sepa-
rately. We have also restricted the analyses to prevalence figures and not examined determi-
nants, which is worthy of future work.
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